Kayyali Chair for Pharmaceutical Industry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box: 2457, Riyadh, 11451, Saudi Arabia.
Mol Biotechnol. 2024 Aug;66(8):1853-1871. doi: 10.1007/s12033-023-00821-z. Epub 2023 Aug 14.
This study aims to highlight the potential use of cTNAs in therapeutic applications. The COVID-19 pandemic has led to significant use of coding therapeutic nucleic acids (cTNAs) in terms of DNA and mRNA in the development of vaccines. The use of cTNAs resulted in a paradigm shift in the therapeutic field. However, the injection of DNA or mRNA into the human body transforms cells into biological factories to produce the necessary proteins. Despite the success of cTNAs in the production of corona vaccines, they have several limitations such as instability, inability to cross biomembranes, immunogenicity, and the possibility of integration into the human genome. The chemical modification and utilization of smart drug delivery cargoes resolve cTNAs therapeutic problems. The success of cTNAs in corona vaccine production provides perspective for the eradication of influenza viruses, Zika virus, HIV, respiratory syncytial virus, Ebola virus, malaria, and future pandemics by quick vaccine design. Moreover, the progress cTNAs technology is promising for the development of therapy for genetic disease, cancer therapy, and currently incurable diseases.
本研究旨在强调 cTNAs 在治疗应用中的潜在用途。COVID-19 大流行导致在疫苗开发中大量使用编码治疗性核酸（cTNAs）的 DNA 和 mRNA。cTNAs 的使用导致治疗领域发生了范式转变。然而，将 DNA 或 mRNA 注射到人体内会将细胞转化为生物工厂，以产生所需的蛋白质。尽管 cTNAs 在冠状病毒疫苗的生产中取得了成功，但它们存在一些局限性，例如不稳定性、无法穿过生物膜、免疫原性以及可能整合到人类基因组中。化学修饰和利用智能药物递送载体解决了 cTNAs 的治疗问题。cTNAs 在冠状病毒疫苗生产中的成功为通过快速疫苗设计消除流感病毒、寨卡病毒、HIV、呼吸道合胞病毒、埃博拉病毒、疟疾和未来的大流行提供了前景。此外，cTNAs 技术的进展有望为遗传性疾病、癌症治疗和目前无法治愈的疾病的治疗发展提供帮助。
